Navigation Links
InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
Date:8/7/2008

BRITISH COLUMBIA, Canada, Aug. 7 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc., (TSX: IXS.V; OTC Bulletin Board: IXSBF) (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announced today that it has launched a large scale primate study of DXL625 (CD20), the company's lead program.

"We are beginning a study in cynomolgus monkeys of DXL625, an antibody directed against the B-cell marker CD20 and enhanced in potency with our DXL(TM) technology," said Thomas Kindt, Ph.D., Chief Scientific Officer. "The test is designed to evaluate toxicity and pharmokinetics of our product and to measure B-cell depletion and recovery in this primate species. This study, which takes multiple months to complete and is part of our drug development plan will generate data moving us toward human clinical trial testing with DXL625."

"Our scientific team has made steady progress in the rapid development of our first preclinical candidate, DXL625 for the prospective treatment of Non-Hodgkin's Lymphoma," said Jeff Morhet, CEO and Chairman. "The primate study is being conducted by Covance Inc. within their world-class facilities in Wisconsin. The launch of this study marks a significant milestone achievement for the company and our lead product DXL625."

InNexus recently announced the addition of a new product designated DXLr120 (CD20). This is the third product added to the growing InNexus pipeline and was developed using new recombinant methods to produce a DXL(TM) anti-CD20 antibody. Upon questions regarding InNexus having a franchise of CD20 products using multiple methods of creation, chemical and recombinant, CEO Morhet said, "I would also think that these products could and should be bundled toward future collaborations with pharmaceutical companies and DXLr120 was developed within our partnership with Royalty Pharma."

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit http://www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.


'/>"/>
SOURCE InNexus Biotechnology Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
2. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
3. New White Paper Details Strategies for Biotechnology Companies to Improve EH&S Compliance
4. Thomson Scientific to Host Pharmaceutical Vision - A Users Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals
5. Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT
6. Luminex Corporation to Present at Biotechnology Industry Organization Investor Forum
7. An Uncommon Eye: Photography Exhibit by Biotechnology Executive at BHCC Gallery
8. Onyx Pharmaceuticals to Present at Biotechnology Industry Organization Investor Forum
9. Leading Biotechnology Company Grows with StayinFront CRM
10. Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
11. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... Do More with OHAUS , With the launch ... supplier in the weighing industry, to extending its expertise across the entire laboratory to ... hybridizations and more, allowing for its customers to 'Do More' in the ...
(Date:6/19/2017)... ... June 19, 2017 , ... As Vice President, Product Services, ... training, implementation, support, and client process and SOP development. , Mr. Guinter brings ... leadership roles for service providers and top-tier pharmaceuticals, and as an independent consultant ...
(Date:6/19/2017)... of Prussia, PA (PRWEB) , ... June 19, 2017 , ... ... life sciences companies for over 50 years. One of the biggest challenges faced by ... Joining the firm’s regulatory affairs services team is Kati Abraham , who is ...
(Date:6/16/2017)... ... June 16, 2017 , ... ... commercialization, has just announced two more sessions of its “From the Helm” Webinar ... on the world of online templates for design control exercises. Led by David ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... 6, 2017 Forecasts by Product ... Readers, by End-Use (Transportation & Logistics, Government & Public ... & Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business ... Are you looking for a definitive report on ... ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
Breaking Biology News(10 mins):